Matches in Wikidata for { <http://www.wikidata.org/entity/Q92604037> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q92604037 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92604037 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92604037 description "scientific article published on 01 March 2019" @default.
- Q92604037 description "wetenschappelijk artikel" @default.
- Q92604037 description "наукова стаття, опублікована 1 березня 2019" @default.
- Q92604037 name "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 name "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 type Item @default.
- Q92604037 label "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 label "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 prefLabel "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 prefLabel "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 P1433 Q92604037-C622B651-6896-4B3A-9390-30A2FAA89435 @default.
- Q92604037 P1476 Q92604037-6CEE243E-38BA-426F-89C2-C7AC7506E394 @default.
- Q92604037 P2093 Q92604037-408322BC-2B20-4F71-938F-640702EE7D86 @default.
- Q92604037 P2093 Q92604037-473B30E8-700D-466C-9258-DD92F2CC2387 @default.
- Q92604037 P2093 Q92604037-5431E94A-C467-414F-9A78-01D5004AC5EB @default.
- Q92604037 P2093 Q92604037-64C29444-5C20-4C3A-81AA-F396F3733C6B @default.
- Q92604037 P2093 Q92604037-7F39949B-1380-4FE6-A7DB-8A57B14C3350 @default.
- Q92604037 P2093 Q92604037-DF00F3B5-F8AD-47B4-94F5-E9C8EAE25615 @default.
- Q92604037 P304 Q92604037-C5ACCD50-8A9C-47BC-88FF-979D4ED514AC @default.
- Q92604037 P31 Q92604037-CDCD8FDE-20C4-47DF-89E2-70AD4FA1572A @default.
- Q92604037 P433 Q92604037-5AD05753-D24D-411B-8594-469CADC94DAA @default.
- Q92604037 P478 Q92604037-7EEFBBB7-3022-4CE4-B155-5DE5014CE7D1 @default.
- Q92604037 P577 Q92604037-76948A50-3F85-4317-A974-47B9F9165637 @default.
- Q92604037 P698 Q92604037-9C8AAD53-CA1F-4F5D-845E-0857F99542A5 @default.
- Q92604037 P921 Q92604037-F0819074-2C77-4710-BC9D-17E170CAEBAF @default.
- Q92604037 P698 30909333 @default.
- Q92604037 P1433 Q25380091 @default.
- Q92604037 P1476 "Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis" @default.
- Q92604037 P2093 "Kim A. Papp" @default.
- Q92604037 P2093 "Leon H. Kircik" @default.
- Q92604037 P2093 "Linda Stein Gold" @default.
- Q92604037 P2093 "Radhakrishnan Pillai" @default.
- Q92604037 P2093 "Susan Harris" @default.
- Q92604037 P2093 "Tina Lin Pharm" @default.
- Q92604037 P304 "279-284." @default.
- Q92604037 P31 Q13442814 @default.
- Q92604037 P433 "3" @default.
- Q92604037 P478 "18" @default.
- Q92604037 P577 "2019-03-01T00:00:00Z" @default.
- Q92604037 P698 "30909333" @default.
- Q92604037 P921 Q10355321 @default.